Advertisement

Topics

Mallinckrodt Acquiring InfaCare and Its Proprietary Jaundice Therapy

09:28 EDT 4 Aug 2017 | PharmPro

Mallinckrodt to acquire InfaCare Pharmaceutical Corporation and stannsoporfin, its proprietary therapy in late-stage development for treatment of newborns at risk for developing severe jaundice. The transaction is expected to close by year end.
Contributed Author: 
Mallinckrodt plc
Topics: 

Original Article: Mallinckrodt Acquiring InfaCare and Its Proprietary Jaundice Therapy

NEXT ARTICLE

More From BioPortfolio on "Mallinckrodt Acquiring InfaCare and Its Proprietary Jaundice Therapy"

Quick Search
Advertisement